CompanyGraph
What stands out
- Earnings significantly exceed cash generation
- Dividend several times the last twelve months' earnings
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionGross margin is 9.4%, lower than 95% of its Biotechnology peers (median 67.2%)
- FinancialsAltman Z-Score 6.84: safe zone
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
What stands out
- Dividend several times the last twelve months' earnings
Dividends view
Yield
0.86%
Annual Rate
CNY 0.22Paid annual
Payout Ratio
311.6%High
Last Ex-Dividend
May 29, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
2.27BCNY338.14M · vs all stocks (USD)
Trailing P/E
353.14xvs Biotechnology peers
Revenue (TTM)
394.29MCNY58.84M · vs all stocks (USD)
Profit Margin
1.67%vs Biotechnology peers
Beta
0.3840xvs all stocks
52-Week Change
-23.11%vs all stocks
Market Capitalization
2.27BCNY338.14M · vs all stocks (USD)
Enterprise Value
1.05BCNY155.95M · vs all stocks (USD)
Trailing P/E
353.14xvs Biotechnology peers
Price to Sales (TTM)
5.75xvs Biotechnology peers
Price to Book (MRQ)
1.20xvs Biotechnology peers
Enterprise to Revenue
2.65xvs Biotechnology peers
Enterprise to EBITDA
73.39xvs Biotechnology peers
Gross Margin
9.43%vs Biotechnology peers
Profit Margin
1.67%vs Biotechnology peers
Operating Margin
-14.98%vs Biotechnology peers
Return on Assets (TTM)
-0.99%vs Biotechnology peers
Return on Equity (TTM)
0.35%vs Biotechnology peers
Revenue (TTM)
394.29MCNY58.84M · vs all stocks (USD)
Revenue per Share (TTM)
4.41CNYUpdated Sep 21, 2026Quarterly Revenue Growth
-16.40%vs Biotechnology peers
Gross Profit (TTM)
55.93MCNY8.35M · vs all stocks (USD)
EBITDA (TTM)
72.66MCNY10.84M · vs all stocks (USD)
Net Income (TTM)
6.60MCNY984.97K · vs all stocks (USD)
Operating Cash Flow (TTM)
-8.83MCNY-1.32M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-175.01MCNY-26.12M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2200CNYUpdated Sep 21, 2026Trailing Annual Dividend Yield
0.86%vs all stocks
Payout Ratio
311.61%vs Biotechnology peers
Revenue
432.73MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
360.52MCNYFY2025 · Dec 31, 2025Gross Profit
72.21MCNYFY2025 · Dec 31, 2025Operating Income
-8.10MCNY-1.21M · vs all stocks (USD)
Pre-tax Income
74.85MCNYFY2025 · Dec 31, 2025Income Tax Expense
10.55MCNYFY2025 · Dec 31, 2025Net Income
64.29MCNYFY2025 · Dec 31, 2025EBIT
74.91MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
72.66MCNYFY2025 · Dec 31, 2025Research & Development
35.80MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
16.27MCNYFY2025 · Dec 31, 2025Other Operating Expenses
4.77MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
7.58MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
63.81KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.7100CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.7100CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
90.56MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
90.56MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
64.29MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
102.97MCNYFY2025 · Dec 31, 2025Free Cash Flow
-42.78MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
361.68MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
64.29MCNYFY2025 · Dec 31, 2025Other Non-cash Items
5.41MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
3.44MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
29.82MCNYFY2025 · Dec 31, 2025Capital Expenditures
-145.75MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.55BCNYFY2025 · Dec 31, 2025Sale of Investments
2.86BCNYFY2025 · Dec 31, 2025Other Investing Activity
-141.60KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
161.82MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-8.26MCNYFY2025 · Dec 31, 2025Other Financing Charges
-79.13MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-87.39MCNYFY2025 · Dec 31, 2025Shares Outstanding
91.67MSharesUpdated Sep 21, 2026Float Shares
30.74MSharesUpdated Sep 21, 2026% Held by Insiders
66.36%vs all stocks
% Held by Institutions
2.23%vs all stocks
Total Cash (MRQ)
1.15BCNY170.96M · vs all stocks (USD)
Total Cash per Share (MRQ)
12.93CNYUpdated Sep 21, 2026Total Debt (MRQ)
845.77KCNY126.21K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0005xvs Biotechnology peers
Current Ratio (MRQ)
9.23xvs Biotechnology peers
Book Value per Share (MRQ)
20.66CNYUpdated Sep 21, 2026Total Assets
2.12BCNY316.33M · vs all stocks (USD)
Total Current Assets
1.51BCNYFY2025 · Dec 31, 2025Total Liabilities
255.33MCNYFY2025 · Dec 31, 2025Total Non-current Assets
610.09MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
57.32MCNYFY2025 · Dec 31, 2025Total Current Liabilities
198.01MCNYFY2025 · Dec 31, 2025Cash
327.47MCNYFY2025 · Dec 31, 2025Cash Equivalents
34.21MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
361.68MCNYFY2025 · Dec 31, 2025Other Short-term Investments
899.07MCNYFY2025 · Dec 31, 2025Accounts Receivable
59.33MCNYFY2025 · Dec 31, 2025Inventory
132.45MCNYFY2025 · Dec 31, 2025Accounts Payable
173.27MCNYFY2025 · Dec 31, 2025Short-term Debt
706.57KCNYFY2025 · Dec 31, 2025Other Current Liabilities
109.24KCNYFY2025 · Dec 31, 2025Long-term Debt
303.57KCNYFY2025 · Dec 31, 2025Common Stock (Book)
91.67MCNYFY2025 · Dec 31, 2025Retained Earnings
681.00MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.86BCNY278.23M · vs all stocks (USD)
Treasury Stock
98.51MCNYFY2025 · Dec 31, 202552-Week Low
21.78CNYUpdated Sep 21, 202652-Week High
38.31CNYUpdated Sep 21, 202652-Week Change
-23.11%vs all stocks
Beta
0.3840xvs all stocks
50-Day MA
25.12CNYUpdated Sep 21, 2026200-Day MA
29.55CNYUpdated Sep 21, 2026Avg 10-Day Volume
704.78KSharesUpdated Sep 21, 2026Avg 30-Day Volume
964.34KSharesUpdated Sep 21, 2026Diluted EPS (TTM)
0.0700CNYUpdated Sep 21, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Debt Falling While Share Count Rises
Debt has fallen for four years while the share count rose over eight.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Cash Backing With OCF Coverage And Cash Near Total Debt
Cash on hand covers most or all of its total debt, and cash flow matches reported earnings.
Reads
How is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 9.4%, lower than 95% of its Biotechnology peers (median 67.2%)Significant
Gross margin: 0.09Industry median: 0.67Industry P5: 0.14Peers compared: 260
P/E ratio is 353.14×, higher than 95% of its Biotechnology peers (median 32.17×)Significant
P/E ratio: 353.143Industry median: 32.17Industry P95: 323.745Peers compared: 260
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)Notable
Debt-to-equity: 0.00Industry median: 0.07Industry P5: 0.00Peers compared: 260
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 984,972.719Operating Cash Flow (USD, TTM): -1,317,129.127
Dividend several times the last twelve months' earningsSignificant
Payout Ratio: 3.12Dividend per Share: 0.22Earnings per Share: 0.07
Financial Health
Altman Z-Score 6.84: safe zoneNotable
Altman Z-Score: 6.84
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Bionote Inc.
Tier 1ProductionApproval-Gated PipelineRule
Benitec Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shapuaisi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanxi C&Y Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jilin Jian Yisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Zhejiang Xinguang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Zhenyuan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Ocugen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Enanta Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Surrozen, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Assure Tech Hangzhou Co., Ltd.
4 interpretationsDebt Falling While Share Count RisesClose Below 40W SMA With ProfitabilityCash Backing With OCF Coverage And Cash Near Total DebtMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Zhubo Design Co. Ltd.
4 interpretationsDebt Falling While Share Count RisesClose Below 40W SMA With ProfitabilityCash Backing With OCF Coverage And Cash Near Total DebtMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Jiangsu Ankura Intelligent Co., Ltd.
4 interpretationsDebt Falling While Share Count RisesClose Below 40W SMA With ProfitabilityCash Backing With OCF Coverage And Cash Near Total DebtMulti-Year Debt Decrease With Cash Near Total Debt And Equity